8-K: Co-Diagnostics Secures Convertible Note Financing

Co-Diagnostics, Inc. has entered into a senior secured convertible loan agreement with J.J. Astor & Co. for up to $3.1 million, with an initial funding of $2.1 million.

Summary

• Co-Diagnostics, Inc. has secured a senior secured convertible loan agreement with J.J. Astor & Co.
• The total loan facility is for up to $3.1 million, with an initial funding of $2.1 million on October 9, 2026.
• The company issued a senior secured convertible installment promissory note with an original principal amount of $2.835 million, reflecting a 1.35x factor rate on the funded amount.
• A 4% origination fee was retained by the lender, resulting in net proceeds of approximately $2.016 million.
• The loan is payable in 30 weekly installments and is secured by a senior-priority lien on substantially all company assets.
• The company may prepay the note without penalty, with a reduced repayment factor of 1.29x if paid within 45 days and no event of default has occurred.
• Upon an event of default, the principal amount increases to 120% of the outstanding balance, with 19% annual default interest.
• The lender can convert the debt into common stock at a conversion price based on a discount to the volume-weighted average price (VWAP), subject to a floor price and ownership limitations.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative development due to the significant dilution risk and the high cost of capital, despite the immediate funding.

Positives

• Secured immediate funding of $2.1 million to support general working capital.
• The loan is secured by a senior-priority lien, indicating a strong commitment to repayment.
• The company has the option to prepay the note without penalty.
• A discount is available for early repayment (within 45 days) if no event of default has occurred, reducing the factor rate to 1.29x.

Negatives

• The original principal amount of the note ($2.835 million) is 1.35 times the funded amount ($2.1 million), indicating a high cost of capital.
• A 4% origination fee was deducted from the initial funding.
• The loan is convertible into common stock, posing a significant risk of dilution for existing shareholders.
• The conversion price is at a discount to market price (90% of lowest VWAP), further increasing dilution potential.
• A floor price of 20% of the Nasdaq minimum price limits conversion but may still lead to substantial share issuance.
• Upon an event of default, the principal amount increases by 20% and carries a high 19% default interest rate.
• The lender can increase its ownership stake to 19.99% with prior notice.
• The company must maintain a minimum cash balance of $250,000 while the notes are outstanding.

Risks

• Significant dilution to existing shareholders due to the convertible nature of the note.
• Potential for the lender to convert debt into equity at a discount, especially if the stock price declines.
• The risk of an Event of Default, which would accelerate the debt, increase the principal amount, and trigger higher interest rates.
• The company's ability to meet its weekly installment payments, especially if ATM proceeds are insufficient.
• The requirement to obtain stockholder approval for issuances exceeding Nasdaq limitations, which may not be granted.
• The company's reliance on the ATM Program for proceeds to service the debt, with potential limitations on distributions to the company.
• The possibility of the lender exercising its option to increase its beneficial ownership cap to 19.99%.

Future Outlook

The company intends to use the net proceeds for general working capital purposes. The loan agreement includes provisions for future borrowings up to $1.0 million, subject to conditions. The company must also seek stockholder approval for certain share issuances related to the loan and Nasdaq listing requirements.

Management Comments

• Dwight H. Egan, CEO of Co-Diagnostics, Inc., executed the note.
• Michael Pope, CEO of J.J. Astor & Co., acknowledged and agreed to the note.

Industry Context

StockSavvy.ai notes that this type of convertible debt financing is common for companies seeking capital for working capital or growth initiatives, particularly those with limited access to traditional bank loans. However, it often comes with significant dilution risk for existing shareholders, a factor that investors closely scrutinize.

Comparison to Industry Standards

• The 1.35x factor rate on the original principal amount compared to the funded amount is higher than typical senior secured debt, suggesting a higher risk profile or cost of capital.
• The 4% origination fee is within the typical range for such financing.
• The 19% default interest rate is high, reflecting the secured nature and potential risks associated with the loan.
• The conversion discount (90% of lowest VWAP) and floor price (20% of Nasdaq minimum price) are aggressive terms, common in venture debt or distressed financing, indicating a potential need for capital and a higher perceived risk by the lender.
• The 9.99% to 19.99% beneficial ownership cap is a standard feature in convertible debt to manage dilution impact on the lender's control.

Stakeholder Impact

• Shareholders: Potential for significant dilution due to the convertible nature of the debt and the discount at which conversion can occur. The company's stock price performance will be critical in determining the extent of dilution.
• Lender (J.J. Astor & Co.): Secured position provides a degree of protection. Potential for significant equity upside if the company's stock price increases, or a high-yield return if the debt is repaid or converted.
• Creditors: The senior secured nature of this debt means it ranks above other unsecured debt, potentially impacting recovery for other creditors in a default scenario.

Next Steps

• The company must make 30 weekly installment payments of $94,500.
• The company must maintain a minimum cash balance of $250,000.
• The company must file a preliminary proxy statement within five business days after funding and hold a stockholder meeting within 30 days after mailing the definitive proxy statement to obtain stockholder approval for certain issuances.
• The company must file a registration statement with the SEC within 30 days from the funding date to register shares for resale by the lender.
• The company must cause the registration statement to become effective within 60 days of the funding date.

Key Dates

Recommendation

The financing provides necessary working capital but comes with significant dilution risk and a high cost of capital. While the secured nature offers some protection, the convertible feature and aggressive terms suggest the company is in a challenging financial position. A 'hold' recommendation reflects the balance between immediate funding needs and the potential negative impact on shareholder value.

Keywords

convertible note, secured loan, debt financing, dilution, capital raise, J.J. Astor & Co., ATM financing, working capital